Onco’Zine - The International Cancer Network- publishes a broad range of topics and timely news updates with information from all oncology disciplines and subspecialties. Onco'Zine is a sponsor-supported, interactive online community for healthcare professionals involved in the management and care of cancer patients.
© 2004 - 2013 Onco'Zine (ISSN 2168-5339) is published by InPress Media Group, LLC.
605 E. Grant Street, Suite 106,
Phoenix, AZ 85004
4960 S. Gilbert Rd, Suite 1-286,
Chandler, AZ 85249
The design of intravenous needleless connectors or NCs plays a substantial role in development of the potentially deadly hospital acquired-catheter related blood stream infection (HA-CRBSI) and the associated risk. Research on different types…Continue
Data presented today at the 2013 Annual Meeting for the American Urological Association by Johns Hopkins University School of Medicine researchers demonstrated that Decipher™ (…Continue
Data from various cancer registries in the United Kingdom shows that Bladder Cancer is a common cancer among men and women in the United Kingdom, with 10.335 new cases diagnosed in 2008.  It is one of the most frequently diagnosed…Continue
Date presented at the 2013 Conference of The American Society of Breast Surgeons (ASBrS) shows promising results for non-surgical cryoablation treatment of breast cancer. The results were presented by Eisuke Fukuma, M.D., Ph.D., Chairman and…Continue
Changes in estrogen breakdown, or metabolism, may be one of the mechanisms by which aerobic exercise lowers a woman’s breast cancer risk. A study discussing data that suggests that exercise influences estrogen metabolism was published earlier…Continue
Our understanding of cancer biology is rapidly increasing, as is the availability and affordability of high throughput technologies for comprehensive molecular characterization of tumors and the individual's own genetic makeup. Thus, the time is right to implement personalized molecular medicine for all patients with cancer. Personalized approaches span the full cancer care spectrum from risk stratification to prevention, screening, therapy, and survivorship programs. Several molecular therapeutics have entered clinical trials creating a huge opportunity to couple genomic markers with this emerging drug tool kit. The number of patients managed in major cancer centers creates a challenge to the implementation of genomic technologies required to successfully deliver on the promise of personalized cancer care. This requires a major investment in infrastructure to facilitate rapid deployment of multiplex, cost-effective, and tissue-sparing assays relevant across multiple tumor lineages in the Clinical Laboratory Improvement Amendments (CLIA) environment. Efforts must be made to ensure that assays are accessible to patients most likely to be enrolled onto molecular-marker–driven trials and that the tests are billable and payable, which will make them accessible to a wide range of patients. As the number of patients and aberrations increase, it will become critical to provide decision support for genomic medicine. Institutional commitment is needed to optimize accessibility and quality of research biopsies and to facilitate novel personalized cancer therapy trials. This article will focus on the challenges and opportunities that accompany the building of infrastructure for personalized cancer therapy.
The use of candidate gene and genome-wide discovery studies in the last several years has led to an expansion of our knowledge of the spectrum of recurrent, somatic disease alleles, which contribute to the pathogenesis of hematologic malignancies. Notably, these studies have also begun to fundamentally change our ability to develop informative prognostic schema that inform outcome and therapeutic response, yielding substantive insights into mechanisms of hematopoietic transformation in different tissue compartments. Although these studies have already had important biologic and translational impact, significant challenges remain in systematically applying these findings to clinical decision making and in implementing new technologies for genetic analysis into clinical practice to inform real-time decision making. Here, we review recent major genetic advances in myeloid and lymphoid malignancies, the impact of these findings on prognostic models, our understanding of disease initiation and evolution, and the implication of genomic discoveries on clinical decision making. Finally, we discuss general concepts in genetic modeling and the current state-of-the-art technology used in genetic investigation.
A majority of cancers are driven by genomic alterations that dysregulate key oncogenic pathways influencing cell growth and survival. However, the ability to harness tumor genetic information for its full clinical potential has only recently become manifest. Over the past several years, the convergence of discovery, technology, and therapeutic development has created an unparalleled opportunity to test the hypothesis that systematic knowledge of genomic information from individual tumors can improve clinical outcomes for many patients with cancer. Rigorous evaluation of this genomics-driven cancer medicine hypothesis will require many logistic innovations that are guided by overarching conceptual advances in tumor genomic profiling, data interpretation, clinical trial design, and the ethical return of genetic results to oncologists and their patients. The results of these efforts and the rigor with which they are implemented will determine whether and how comprehensive tumor genomic information may become incorporated into the routine care of patients with cancer.
Prostate cancer is the most common type of cancer in men and the second leading cause of cancer death in men in the United States. The recent surge of high-throughput sequencing of cancer genomes has supported an expanding molecular classification of prostate cancer. Translation of these basic science studies into clinically valuable biomarkers for diagnosis and prognosis and biomarkers that are predictive for therapy is critical to the development of precision medicine in prostate cancer. We review potential applications aimed at improving screening specificity in prostate cancer and differentiating aggressive versus indolent prostate cancers. Furthermore, we review predictive biomarker candidates involving ETS gene rearrangements, PTEN inactivation, and androgen receptor signaling. These and other putative biomarkers may signify aberrant oncogene pathway activation and provide a rationale for matching patients with molecularly targeted therapies in clinical trials. Lastly, we advocate innovations for clinical trial design to incorporate tumor biopsy and molecular characterization to develop biomarkers and understand mechanisms of resistance.
Ongoing global genome characterization efforts are revolutionizing our knowledge of cancer genomics and tumor biology. In parallel, information gleaned from these studies on driver cancer gene alterations—mutations, copy number alterations, translocations, and/or chromosomal rearrangements—can be leveraged, in principle, to develop a cohesive framework for individualized cancer treatment. These possibilities have been enabled, to a large degree, by revolutionary advances in genomic technologies that facilitate systematic profiling for hallmark cancer genetic alterations at increasingly fine resolutions. Ongoing innovations in existing genomics technologies, as well as the many emerging technologies, will likely continue to advance translational cancer genomics and precision cancer medicine.
Immunotherapy has become a well-accepted treatment for advanced prostate cancer, and researchers are now seeking to fine-tune our knowledge of how to use it most effectively. Dr. John Corman, medical ...
Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifoca...
Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer...
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based o...